Regorafenib

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2501 publications

Efficacy of ripretinib in advanced gastrointestinal stromal tumor and treatment options after resistance: a retrospective real-world study​

Efficacy of ripretinib in advanced gastrointestinal stromal tumor and treatment options after resistance: a retrospective real-world study​

Journal: Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
Published: September 07, 2026

Albumin Nanoparticle-Mediated Codelivery of Regorafenib and Paclitaxel Boosts Chemoimmunotherapy of Peritoneal Metastases.

Albumin Nanoparticle-Mediated Codelivery of Regorafenib and Paclitaxel Boosts Chemoimmunotherapy of Peritoneal Metastases.

Journal: Small methods
Published: August 11, 2026

Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer: a propensity score matched analysis of 708 patients.

Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer: a propensity score matched analysis of 708 patients.

Journal: Journal for immunotherapy of cancer
Published: August 10, 2026

Plant-derived natural products against hepatocellular carcinoma: chemical diversity, mechanisms of action, and organ-based classification.

Plant-derived natural products against hepatocellular carcinoma: chemical diversity, mechanisms of action, and organ-based classification.

Journal: Natural product research
Published: August 07, 2026

WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.

WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.

Journal: Oncotarget
Published: July 21, 2026

Reduced-Dose Regorafenib for Recurrent Glioblastoma: A Safety and Outcome Analysis.

Reduced-Dose Regorafenib for Recurrent Glioblastoma: A Safety and Outcome Analysis.

Journal: Cancers
Published: July 12, 2026

Regorafenib and metronomic capecitabine, cyclophosphamide, and aspirin in refractory metastatic colorectal cancer: results from the REPROGRAM-01 single-arm phase II trial.

Regorafenib and metronomic capecitabine, cyclophosphamide, and aspirin in refractory metastatic colorectal cancer: results from the REPROGRAM-01 single-arm phase II trial.

Journal: ESMO gastrointestinal oncology
Published: July 06, 2026

Eight-month sustained delivery of regorafenib from subconjunctival crystal depots for inhibition of corneal neovascularization.

Eight-month sustained delivery of regorafenib from subconjunctival crystal depots for inhibition of corneal neovascularization.

Journal: International journal of pharmaceutics
Published: June 10, 2026

Comparing the Effectiveness and Safety of Different Third-Line Management Options for Patients with Metastatic Colorectal Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-Analysis.

Comparing the Effectiveness and Safety of Different Third-Line Management Options for Patients with Metastatic Colorectal Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-Analysis.

Journal: Cancers
Published: June 08, 2026

Anionic Nanoparticles Co-Loaded with Regorafenib/Paclitaxel for Macrophage-Mediated Chemoimmunotherapy against Colorectal Peritoneal Metastases.

Anionic Nanoparticles Co-Loaded with Regorafenib/Paclitaxel for Macrophage-Mediated Chemoimmunotherapy against Colorectal Peritoneal Metastases.

Journal: Nano letters
Published: May 22, 2026

Efficacy and safety of TAS-102 followed by regorafenib or reverse sequence in later-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis.

Efficacy and safety of TAS-102 followed by regorafenib or reverse sequence in later-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis.

Journal: Chinese clinical oncology
Published: May 21, 2026

Unravelling bioanalytical innovations, degradation processes, and impurity landscapes of VEGFR inhibitors.

Unravelling bioanalytical innovations, degradation processes, and impurity landscapes of VEGFR inhibitors.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
Published: May 17, 2026
Showing 1-12 of 2,501

Last Updated: 09/26/2026